Scopus BioPharmaNASDAQ: SCPS

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Scopus BioPharma is in the Healthcare sector

Scopus BioPharma is in the Biotechnology industry

Scopus BioPharma is headquartered in United States

Scopus BioPharma initial public offering (IPO) was on 16 December 2020

https://scopusbiopharma.com

No, Scopus BioPharma is not included in the S&P 500 index

No, Scopus BioPharma is not included in the NASDAQ 100 index

No, Scopus BioPharma is not included in the Dow Jones index